• 1. Excimer emission and magnetoluminescence of radical-based zinc(ii) complexes doped in host crystals?
  Shojiro Kimura,Tetsuro Kusamoto Chem. Commun., 2020,56, 11195-11198
• 2. Excellent lithium ion storage property of porous MnCo2O4 nanorods?
  Peiyuan Zeng,Xiaoxiao Wang,Ming Ye,Qiuyang Ma,Jianwen Li,Wanwan Wang,Baoyou Geng,Zhen Fang RSC Adv., 2016,6, 23074-23084
• 3. Excellent kinetics of single-phase Gd-doped ceria fuel electrodes in solid oxide cells?
  Andreas Nenning,Manuel Holzmann,Jürgen Fleig,Alexander K. Opitz Mater. Adv., 2021,2, 5422-5431
• 4. Emergence of microfluidic wearable technologies
  Joo Chuan Yeo,Kenry Lab Chip, 2016,16, 4082-4090
• 5. Emulsion technologies for multicellular tumour spheroid radiation assays?
  Kay S. McMillan,Anthony G. McCluskey,Annette Sorensen,Marie Boyd,Michele Zagnoni Analyst, 2016,141, 100-110

• Solvents and Organic Chemicals Organic Compounds Hydrocarbons Saturated hydrocarbons Alkanes

Introduction to Propargyl-PEG5-beta-D-galactose (CAS No. 1397682-63-1)

Propargyl-PEG5-beta-D-galactose, a compound with the chemical identifier CAS No. 1397682-63-1, represents a significant advancement in the field of biochemical research and pharmaceutical development. This innovative molecule, featuring a propargyl group linked to a PEG5 (polyethylene glycol with a molecular weight of 500 Da) backbone and terminated with a beta-D-galactose moiety, exhibits unique properties that make it highly valuable for various applications.

The structure of Propargyl-PEG5-beta-D-galactose is meticulously designed to leverage the benefits of each component. The propargyl group, characterized by its triple bond functionality, provides a versatile site for further chemical modifications, enabling the synthesis of more complex derivatives. This feature is particularly useful in drug design, where precise molecular modifications can enhance bioavailability and target specificity.

The incorporation of PEG5 into the molecule offers significant advantages in terms of stability and biocompatibility. Polyethylene glycol (PEG) is widely recognized for its ability to improve the solubility and circulation time of bioactive molecules in biological systems. By linking PEG5 to beta-D-galactose, the compound achieves enhanced pharmacokinetic properties, which are crucial for therapeutic applications.

The terminal beta-D-galactose moiety adds another layer of functionality to Propargyl-PEG5-beta-D-galactose. Beta-D-galactose is a natural sugar that plays a vital role in cell recognition and adhesion processes. Its presence in this compound makes it an excellent candidate for applications involving cell targeting and receptor-mediated delivery systems.

In recent years, Propargyl-PEG5-beta-D-galactose has garnered attention in the field of targeted drug delivery systems. The combination of its propargyl group for further derivatization, PEG5 for improved biocompatibility, and beta-D-galactose for specific cell targeting has opened new avenues in oncology and immunotherapy. Researchers have been exploring its potential in developing targeted therapies for cancer, where precise delivery of chemotherapeutic agents to tumor cells while minimizing side effects is paramount.

One of the most exciting applications of Propargyl-PEG5-beta-D-galactose is in the realm of vaccine development. The beta-D-galactose moiety can be utilized to target specific immune cells, such as B-cells and macrophages, enhancing the body's immune response to pathogens. This has significant implications for designing more effective vaccines against infectious diseases.

The compound's unique structure also makes it suitable for use in diagnostic imaging techniques. By attaching fluorescent or radioactive labels to the propargyl group, researchers can develop novel contrast agents for magnetic resonance imaging (MRI) and positron emission tomography (PET). These imaging agents can provide detailed insights into biological processes at the cellular level, aiding in early disease detection and monitoring treatment efficacy.

The versatility of Propargyl-PEG5-beta-D-galactose extends to its use as a building block for more complex biomaterials. The propargyl group allows for further functionalization, enabling the creation of hybrid molecules that combine the properties of multiple biomolecules. This approach has been particularly useful in developing smart drug delivery systems that can respond to specific physiological triggers.

In conclusion, Propargyl-PEG5-beta-D-galactose (CAS No. 1397682-63-1) is a multifaceted compound with broad applications in pharmaceuticals, diagnostics, and biotechnology. Its unique structural features make it an invaluable tool for researchers seeking to develop innovative therapies and diagnostic tools. As our understanding of biological systems continues to evolve, the potential uses for Propargyl-PEG5-beta-D-galactose are likely to expand even further.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)